Related Experiment Video
Updated: Mar 14, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
Katsuya Nakai1, Mien-Chie Hung2, Hirohito Yamaguchi3
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer CenterUSA; Department of Breast Oncology, Juntendo University School of MedicineBunkyo-ku, Tokyo, Japan.
Abstract:
Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15-20% of breast cancers and is the most aggressive breast cancer subtype. There are currently no effective therapies against metastatic TNBC. Compared with other breast cancer subtypes, EGFR is frequently overexpressed in TNBC and a potential therapeutic target for this disease. There are two types of EGFR inhibitors, small molecular tyrosine kinase inhibitor (TKI) and monoclonal antibody (mAb), for the treatment of cancers, such as non-small cell lung cancer and colorectal cancer. For breast cancer, however, the clinical trials of EGFR inhibitors have failed due to low response rates. Because a small portion of patients do demonstrate response to EGFR inhibitors, it may be necessary to stratify patients to enhance the efficacy of EGFR inhibitors in TNBC and to develop the effective combination therapy for this patient population. In this review, we describe some of the molecular mechanisms underlying EGFR inhibitor sensitivity and further discuss the possible therapeutic strategies to increase the efficacy of EGFR inhibitors in TNBC.
Insights
Triple-negative breast cancer (TNBC) is aggressive with no effective therapies. This review explores strategies to improve epidermal growth factor receptor (EGFR) inhibitor efficacy in TNBC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Triple-negative breast cancer (TNBC) represents 15-20% of breast cancers and is highly aggressive.
- Metastatic TNBC currently lacks effective therapeutic options.
- Epidermal growth factor receptor (EGFR) is overexpressed in TNBC, presenting a potential therapeutic target.
Purpose of the Study:
- To review molecular mechanisms of EGFR inhibitor sensitivity in TNBC.
- To discuss strategies for enhancing EGFR inhibitor efficacy in TNBC.
- To explore potential combination therapies for TNBC.
Main Methods:
- Literature review of studies on EGFR inhibitors in cancer.
- Analysis of molecular mechanisms underlying EGFR inhibitor response.
- Discussion of clinical trial outcomes and patient stratification.
Main Results:
- EGFR inhibitors have shown limited success in breast cancer clinical trials.
- A subset of TNBC patients responds to EGFR inhibitors, suggesting potential for targeted therapy.
- Understanding EGFR inhibitor sensitivity mechanisms is crucial for therapeutic development.
Conclusions:
- Patient stratification is necessary to improve EGFR inhibitor efficacy in TNBC.
- Developing effective combination therapies is essential for treating TNBC.
- Further research into molecular mechanisms can guide novel therapeutic strategies for TNBC.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:49Cancer Therapies